ClinicalTrials.gg
TerminatedNCT02352285AQUATICUpdated Jun 14, 2017

Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure

A Phase 4 interventional study of Tolvaptan and Placebo in Heart Failure With Hyponatremia, sponsored by Korea Otsuka Pharmaceutical Co., Ltd.. Terminated at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-06-14.

Sponsored by Korea Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.

Enrollment
11th of 19
58 · median 60
Started
2012
with 2 others
Phase 4
9 of 19
none open now
Registered
11th of 19
by date
Lead sponsor
1 of 19
Korea Otsuka Pharmaceutical Co., Ltd.

Among the 19 studies testing tolvaptan in Heart Failure, this one is the 11th largest by enrollment, is one of 3 that started in 2012, is one of 9 in phase 4, and was the 11th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing tolvaptan in Heart Failure as a file.
02

Study summary

The objective is to evaluate the efficacy and safety on the tolvaptan for increasing serum Na levels in patients with worsening heart failure and hyponatremia.

Read the detailed description

This is a phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel-group interventional study comparing tolvaptan (15 to 60 mg) to placebo in adult patients hospitalized (or admission to emergency room) due to worsening of heart failure and dilutional hyponatremia. All patients will be on standard therapy for heart failure.

03

Conditions studied

  • Heart Failure With Hyponatremia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients hospitalized due to heart failure with hyponatremia (except hypovolemic) (defined as serum Na \< 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) prior to randomization.
  2. Male and female patients aged ≥ 20 years.
  3. (NYHA) class III/Ⅳ
  4. Signs of extracellular volume expansion, defined as two or more of the following: JVD, peripheral edema, dyspnea or pulmonary congestion.
  5. B-type natriuretic peptide (BNP) ≥ 150 pg/mL or N terminal (NT)-proBNP ≥ 450 pg/mL.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant, breast feeding, or of who are not using acceptable methods
  2. Patients with hyponatremia in hypovolemic states, defined as the presence of clinical and historical evidence of extracellular fluid volume depletion
  3. Patients unable to sense or respond to thirst.
  4. Patients who are likely to require prolonged hospitalization for reasons other than chronic heart failure (CHF)
  5. Patients with recent prior treatment for hyponatremia
  6. Patients with severe hyponatremia symptoms requiring immediate intervention with hypertonic saline
  7. Patients with causes of neurological symptoms, which are attributable to psychological (psychoses), structural (dementia of the Alzheimer's type, post-infarct dementia) or other metabolic causes
  8. Patients with acute and transient hyponatremia associated with head trauma or severe neurological injury
  9. Patients with a history of hyponatremia known to be due to severe, untreated hypothyroidism/adrenal insufficiency.
  10. Patients with psychogenic polydipsia.
  11. Patients with systolic BP \< 90 mmHg at screening.
  12. Patients with a history of and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril), or tolvaptan.
  13. Patients with a history of drug or medication abuse within the 3 months prior to screening, or current alcohol abuse.
  14. Patients with uncontrolled diabetes mellitus
  15. Patients with a current urinary tract obstruction
  16. Anuric patients.
  17. Patients with a serum creatinine > 3.5 mg/dL at screening.
  18. Terminally ill patients or patients with a moribund condition who have little chance of short-term survival.
  19. Patients whose hyponatremia is the result of any medication that cannot safely be withdrawn, such as anti-convulsants and anti psychotics
  20. Patients receiving desmopressin within 2 days of screening.
  21. Patients who have participated in another drug trial within the past 30 days.
  22. Any patient who, in the opinion of the investigator, would not be able to comply with the study drug administration or study procedures, or whose overall medical condition would prohibit their participation in the study.
  23. Patients treated and/or to be treated with strong cytochrome P450 (CYP) 3A inhibitors
  24. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose- galactose malabsorption.
  25. Patients with a or ALT > 2.5 or total > 2mg/dL
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Tolvaptan

    Tovaptan tablet 15mg, 30mg, 60mg, once a day, oral

    Drug: Tolvaptan

  • Placebo comparator
    placebo

    placebo tablet 15mg, 30mg, 60mg, once a day, oral

    Drug: Placebo

Interventions

  • Start with 15mg to titrate upwards to 30mg to 60mg, once a daily

    Also known as: Samsca

  • DrugPlacebo

    Start with 15mg to titrate upwards to 30mg to 60mg, once a daily

06

What researchers measure

Primary outcomes

  1. Average daily AUC of change from baseline in serum Na level to day 4 within the double-blind treatment period

    Time frame: from baseline to day 4

Secondary outcomes

  1. Average amount of furosemide used during hospitalization.

    Time frame: from day 1 to discharge date (up to subject condition day 2 ~ day 30)

  2. Average amount of furosemide used during out-patient period.

    Time frame: from baseline to day 30 and day 60

07

Study locations

1 site
  • Seoul National University Bundang Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2012 to primary completion in Jan 2017, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2012
First posted
Feb 2, 2015
StartActual
Dec 2012
Primary completionActual
Jan 2017
CompletionActual
Jan 2017
Last update
Jun 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02352285
Responsible party
Sponsor
First posted
Feb 2, 2015
Start date
Dec 2012
Primary completion
Jan 2017
Completion
Jan 2017
Last update
Jun 14, 2017

Study contacts

Dongju Choi, MD
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion